Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Operating Expenses: 2019-2024

Historic Other Operating Expenses for Coherus Oncology (CHRS) over the last 6 years, with Dec 2024 value amounting to $117.6 million.

  • Coherus Oncology's Other Operating Expenses rose 36.35% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 264.70%. This contributed to the annual value of $117.6 million for FY2024, which is 141.31% up from last year.
  • Coherus Oncology's Other Operating Expenses amounted to $117.6 million in FY2024, which was up 141.31% from -$284.6 million recorded in FY2023.
  • In the past 5 years, Coherus Oncology's Other Operating Expenses ranged from a high of $117.6 million in FY2024 and a low of -$369.4 million during FY2022.
  • Its 3-year average for Other Operating Expenses is -$178.8 million, with a median of -$284.6 million in 2023.
  • As far as peak fluctuations go, Coherus Oncology's Other Operating Expenses crashed by 741.49% in 2022, and later spiked by 141.31% in 2024.
  • Over the past 5 years, Coherus Oncology's Other Operating Expenses (Yearly) stood at $37.7 million in 2020, then soared by 52.90% to $57.6 million in 2021, then tumbled by 741.49% to -$369.4 million in 2022, then rose by 22.97% to -$284.6 million in 2023, then spiked by 141.31% to $117.6 million in 2024.